Background We performed a prospective study to evaluate the efficacy of activated charcoal
(AC) to prevent irinotecan‐induced diarrhea (IID). Procedure We designed a prospective …

Purpose The dose-limiting toxicity of irinotecan (CPT-11; Camptosar) is delayed-onset
diarrhea, with an incidence at the grade 3 to 4 level of 20% to 35%. SN38, its active moiety …

Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea
associated with protracted irinotecan administration may reduce morbidity and improve dose …

It has been reported that 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino] carbonyloxy‐
camptothecin (CPT‐11) and its active metabolite, 7‐ethyl‐10‐hydroxy‐camptothecin (SN …

Aim and background Intestinal alkalization could prevent irinotecan associated diarrhea
modulating some chemical equilibria between irinotecan metabolites. The aim of this study …

Abstract Irinotecan (CPT-11) treatments induce severe diarrhoea at a rate of> 40%. In
clinical trials, we evaluated the preventing effects of oral alkalization, which has been …

Alkalization of the intestinal tract by oral administration of sodium bicarbonate has been
reported to be a promising method for preventing delayed diarrhea, a dose-limiting toxicity in …

Purpose Irinotecan is active against a variety of malignancies; however, severe diarrhea
limits its usefulness. In our phase I study, the intravenous formulation of irinotecan was …

Camptotheca acuminata, and presents a wide spectrum of anti-tumor activity through the
inhibition of DNA topoisomerase I. It is an important, relatively new chemotherapeutic drug …

Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …